CurrentCapital BluecrossPolicy AHS G2007

Prostate Biopsy Specimen Analysis

Coverage criteria for pathological examination of prostate biopsy specimens, including initial and repeat biopsies, who meets coverage, and limitations such as saturation biopsy exclusions. Applies to Capital Bluecross members and providers submitting requests for prostate biopsy specimen analysis.

Policy Summary

PayerCapital Bluecross

PolicyProstate Biopsy Specimen Analysis

Policy CodePolicy AHS G2007

Change TypeNo material change

Effective Date

Next Review Date

Key ActionSubmit pathology for standard 12-core extended or follow-up biopsies; saturation biopsy specimens are not covered.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12-corestandard extended sampling recommended for initial diagnosis

24maximum cores cited for saturation biopsy

22-33%detection rate of saturation biopsy on repeat biopsy

PROMIS N=576study comparing mpMRI, TRUS, and TPM

NPV 89%

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Covered indications

Covered when ALL of the following are met

Initial diagnostic biopsy: Pathological examination of tissue obtained from a prostate biopsy involving 12-core extended sampling for initial diagnosis following abnormal PSA, palpable nodule on DRE, or suspicious radiologic findings.12-core

One vial per sextant, no more than two cores per vial

Follow-up biopsy after negative initial biopsy: Pathological examination of tissue from a follow-up prostate biopsy (excluding prostate saturation biopsy) when clinical suspicion for prostate cancer persists after an initial negative biopsy.exclude saturation biopsy

May consider mpMRI and MRI-targeted biopsy per guideline recommendations

Not medically necessary / Excluded

Not covered

Saturation biopsy specimen analysis: Pathological examination of tissue obtained from a prostate saturation biopsy does not meet coverage criteria due to insufficient evidence of benefit and higher complication rates.up to 24 cores

Saturation biopsy may detect more cancers on repeat biopsy (approx. 22–33%) but is associated with increased complications; excluded from coverage.

Covered when guideline-based conditions are met

Preferred and recommended approaches based on guideline synthesis

Initial biopsy preferred approach: When MRI-targeting capabilities are available, perform a combination of systematic (extended pattern, at least 12 cores) and MRI-targeted biopsy at initial biopsy.

NCCN prefers combined systematic + targeted at initial biopsy; ACR and EAU support MRI use prior to biopsy

Targeted biopsy techniques: Allowed targeted techniques include cognitive (visual) targeting, TRUS–MRI fusion platforms, and in‑bore MRI‑guided biopsy.

Listed by NCCN as targeted options

Repeat biopsy considerations: For persistently elevated or rising PSA or ongoing clinical suspicion after a negative biopsy, consider multiparametric MRI followed by targeted biopsy; for active surveillance, repeat biopsy generally no more often than every 12 months unless clinically indicated.

NCCN and EAU guidance; ACR supports MRI-targeted approaches

Pathological examination of tissue obtained from a prostate saturation biopsy is specifically excluded from meeting coverage criteria. The policy states that saturation biopsy — which can involve extensive sampling of the prostate with up to 24 cores — DOES NOT MEET COVERAGE CRITERIA for diagnosis, staging, or management due to insufficient evidence of patient benefit and higher complication rates.

Saturation biopsy may have a role after one or more negative TRUS-guided biopsies because it can increase cancer detection on repeat sampling (detection ~22–33% on repeat biopsy), but this increased detection is balanced by a higher incidence of complications; therefore, pathological analysis of saturation biopsy specimens is excluded from coverage.

The NCCN Guidelines do not support routine anteriorly directed biopsy as part of the initial biopsy protocol. Anterior sampling may be added to an extended protocol in the repeat-biopsy setting when PSA remains persistently elevated, but it is not recommended as routine for first-time biopsy.

NCCN also states that a saturation biopsy strategy is not recommended for all individuals with prior negative biopsies given the demonstrated benefits of multiparametric MRI and MRI-targeted biopsy in that population; consideration of mpMRI followed by targeted biopsy is preferred when clinical suspicion persists after a negative biopsy.

Pathological examination of tissue obtained from a prostate saturation biopsy does not meet coverage criteria. The policy explicitly indicates that saturation biopsy specimens are excluded from coverage due to lack of sufficient published evidence confirming clinical benefit.

Providers should therefore not expect coverage for surgical pathology analysis of saturation biopsy cores submitted for diagnosis, staging, or management of prostate cancer under this policy.

The NCCN does not recommend a routine saturation biopsy strategy for all patients with prior negative biopsies. Instead, the guideline emphasizes the value of mpMRI and MRI-targeted biopsy approaches, reserving extensive sampling strategies for select cases where imaging and clinical context justify further sampling.

When clinical suspicion remains after negative image-guided biopsies, NCCN suggests consideration of MRI followed by targeted biopsy for those at higher risk (for example, persistently elevated or rising PSA) rather than a blanket approach of saturation sampling for all patients.

Coding and Thresholds

Applicable HCPCS/CPT reference codesHCPCS

G0416

Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method

PSA threshold historically used

Historical PSA referral threshold>= 4.0 ng/mL

ACS guidance for intermediate PSAPSA 2.5–4.0 ng/mL: consider individualized risk assessment (race, family history, age, DRE)

Context noteACS states PSA >=4.0 ng/mL historically used to recommend referral for further evaluation or biopsy

Repeat biopsy interval (active surveillance)

Active surveillance repeat biopsy intervalNo more often than every 12 months unless clinically indicated (eg, PSA increase)

PopulationPatients on active surveillance with >10 years life expectancy per NCCN

Provider Actions & Operational Notes

Denial Risk

Coverage requirement for biopsy specimen analysis

Pathological examination of prostate biopsy specimens meets coverage when performed as an initial diagnostic extended 12-core sampling or as a follow-up biopsy after a negative initial biopsy when clinical suspicion persists. Do not submit pathology for prostate saturation biopsy specimens — pathological examination of tissue obtained from a prostate saturation biopsy does not meet coverage and may be denied.

Initial diagnostic biopsy: extended ≥12-core systematic sampling meets coverage when clinical indications are present (eg, abnormal PSA, palpable nodule, or suspicious imaging).
Repeat biopsy: pathological examination of follow-up prostate biopsy specimens meets coverage when clinical suspicion for prostate cancer persists after a negative initial biopsy (saturation biopsy excluded).
Saturation biopsy exclusion: saturation biopsy specimens are not covered and may be denied.

Prior Authorization

Imaging-guided approach before repeat biopsy

Background

Prostate cancer encompasses a spectrum from indolent to aggressive disease. Indications for prostate biopsy commonly include an abnormal prostate-specific antigen (PSA), a palpable nodule on digital rectal examination (DRE), or suspicious imaging findings; in these situations, systematic extended-core biopsy (commonly an extended 12-core pattern) is the validated approach for initial diagnosis and MEETS COVERAGE CRITERIA.

Systematic TRUS-guided sampling evolved from sextant techniques to extended-core patterns because extended sampling detects substantially more cancers. Saturation biopsy is an extensive sampling method (up to 24 cores) that may increase detection on repeat biopsy but carries higher complication rates and is not appropriate for routine initial screening.

Guideline-based practice increasingly supports the use of multiparametric MRI (mpMRI) and MRI-targeted biopsy techniques. When available, combining systematic (≥12-core) and MRI-targeted biopsy at initial sampling yields higher detection of clinically significant cancer. For persistent clinical suspicion after a negative biopsy, consider mpMRI with targeted biopsy rather than routine saturation sampling; repeat surveillance biopsies are generally performed no more often than every 12 months unless clinically indicated.

Definitions

Saturation biopsy — Definition and typical maximum cores

DefinitionExtensive sampling of the prostate obtaining up to ~24 core samples (saturation biopsy)

Typical maximum cores citedUp to 24 cores

Policy coverage stancePathological examination of tissue obtained from a prostate saturation biopsy does not meet coverage criteria

SBx / TRUS biopsy — Definition

DefinitionTransrectal ultrasound-guided systematic sampling of the prostate (eg, extended 12-core pattern)

Recommended initial patternExtended pattern of at least 12 cores validated to enhance detection compared with sextant sampling

Policy Summary

PayerCapital Bluecross

PolicyProstate Biopsy Specimen Analysis

Policy CodePolicy AHS G2007

Change TypeNo material change

Effective Date

Next Review Date

Key ActionSubmit pathology for standard 12-core extended or follow-up biopsies; saturation biopsy specimens are not covered.

SourceLink

On This Page

Approach preference (route): Transperineal biopsy is preferred over transrectal biopsy when feasible because it yields higher detection of clinically significant cancer and fewer adverse events.

Recommendation by ESMO

Clinical triggerPerform sooner than 12 months if clinically indicated (eg, rising PSA)

When clinical suspicion persists after a negative biopsy, obtain multiparametric MRI (mpMRI) and consider MRI-targeted biopsy prior to repeat biopsy. Imaging-guided approaches (mpMRI followed by MRI-targeted biopsy or combined systematic plus targeted biopsy) are supported to improve detection of clinically significant prostate cancer.

Preferred approach before repeat biopsy: mpMRI followed by MRI-targeted biopsy when mpMRI is suspicious.
If mpMRI is negative but clinical suspicion remains, clinical judgment may warrant repeat biopsy; consider targeted and systematic sampling.
Combined approach: when MRI-targeting is available, perform combined systematic (extended ≥12-core) plus MRI-targeted biopsy for higher yield of clinically significant cancer.

Documentation Required

Specimen handling and sampling

Specimens should be handled and sampled according to standard recommendations: use an extended 12-core systematic sampling for initial diagnostic biopsies and submit cores in a way that preserves anatomic localization.

One vial per sextant, with no more than two cores per vial.
Use extended 12-core systematic template (including far-lateral/apical cores) for initial biopsy; avoid routinely sampling transition zone or taking >12 cores for initial diagnostic biopsy.
When resampling after a negative biopsy, additional cores or targeted cores (including anterior/apical as indicated) may be added based on imaging and clinical suspicion.

Note

Conflict with government policy

If there is a conflict between this policy and any applicable government policy (eg, Local Coverage Determinations or National Coverage Determinations for Medicare, or state Medicaid policies), the government policy supersedes and will be used to make coverage determinations.

Check applicable LCDs/NCDs and state Medicaid rules for the most up-to-date Medicare and Medicaid coverage determinations.

Standard approach for systematic sampling; often combined with MRI-targeted biopsy when available

mpMRI — Multiparametric MRI definition and role in guiding targeted biopsies

DefinitionMultiparametric MRI (mpMRI): multi-parametric magnetic resonance imaging of the prostate used for risk stratification and to guide targeted biopsies

Clinical rolempMRI can identify individuals who may avoid unnecessary biopsy and is recommended before repeat biopsy; mpMRI-first pathway (mpMRI → targeted biopsy if suspicious) is supported

Performance notePROMIS: mpMRI sensitivity 93% and NPV 89% for clinically significant cancer, supporting its use to reduce unnecessary biopsies

MRI-targeted biopsy — MRI-targeting techniques

DefinitionMRI-targeted biopsy: techniques that target lesions identified on mpMRI, including cognitive (visual) targeting, TRUS–MRI fusion platforms, and direct in‑bore MRI-guided biopsy

Clinical advantageTargeted approaches increase detection of clinically significant cancer and are recommended to be combined with systematic sampling when available

Recommended useNCCN supports targeted techniques (cognitive, fusion, in‑bore) and prefers combined systematic + targeted biopsy at initial biopsy when MRI-targeting available

PI-RADS — Definition and cited thresholds for targeted biopsy decisions

DefinitionPI-RADS: Prostate Imaging Reporting and Data System score used to categorize suspicion on mpMRI

ESMO cited threshold for positive mpMRIPI-RADS 2–3 cited by ESMO as definitions for positive MRI prompting targeted biopsy (ESMO: when mpMRI positive [PI-RADS 2–3], perform targeted biopsy)

Negative mpMRI guidanceESMO: when mpMRI negative (PI-RADS <2) and clinical suspicion is low, biopsy can be omitted